NASDAQ:BNGO - BioNano Genomics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.74 +0.32 (+7.24 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$4.74
Today's Range$4.74 - $4.74
52-Week Range$3.50 - $10.00
Volume135 shs
Average Volume41,117 shs
Market Capitalization$47.87 million
P/E Ratio-1.82
Dividend YieldN/A
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its instruments and consumables for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in North America, Europe, the Middle East, India, Africa, and the Asia Pacific. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Receive BNGO News and Ratings via Email

Sign-up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Current SymbolNASDAQ:BNGO



Sales & Book Value

Annual Sales$12 million
Book Value$1.01 per share



Market Cap$47.87 million
Next Earnings Date6/13/2019 (Estimated)
OptionableNot Optionable

BioNano Genomics (NASDAQ:BNGO) Frequently Asked Questions

What is BioNano Genomics' stock symbol?

BioNano Genomics trades on the NASDAQ under the ticker symbol "BNGO."

How were BioNano Genomics' earnings last quarter?

BioNano Genomics Inc (NASDAQ:BNGO) issued its earnings results on Thursday, March, 14th. The company reported ($0.62) EPS for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.14. The firm had revenue of $4.01 million for the quarter, compared to analyst estimates of $3.71 million. View BioNano Genomics' Earnings History.

When is BioNano Genomics' next earnings date?

BioNano Genomics is scheduled to release their next quarterly earnings announcement on Thursday, June 13th 2019. View Earnings Estimates for BioNano Genomics.

What price target have analysts set for BNGO?

2 brokers have issued 1-year price targets for BioNano Genomics' shares. Their predictions range from $11.00 to $12.00. On average, they anticipate BioNano Genomics' stock price to reach $11.50 in the next year. This suggests a possible upside of 142.6% from the stock's current price. View Analyst Price Targets for BioNano Genomics.

What is the consensus analysts' recommendation for BioNano Genomics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNano Genomics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioNano Genomics.

What are Wall Street analysts saying about BioNano Genomics stock?

Here are some recent quotes from research analysts about BioNano Genomics stock:
  • 1. According to Zacks Investment Research, "BioNano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents. BioNano Genomics, Inc. is based in San Diego, United States. " (3/22/2019)
  • 2. Maxim Group analysts commented, "Bionano reported (on 3/14) 4Q18 and YE18 with revenue of $4M and $12M, respectively, representing y/y growth of 41% and 26%. The company reported a net loss for the year of ($18.5M) and ended the period with $16.5M in cash on the balance sheet." (3/18/2019)

Has BioNano Genomics been receiving favorable news coverage?

Media coverage about BNGO stock has been trending negative on Saturday, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioNano Genomics earned a coverage optimism score of -2.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.

Who are some of BioNano Genomics' key competitors?

What other stocks do shareholders of BioNano Genomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNano Genomics investors own include Nuvista Energy (NVA), Arcadia Biosciences (RKDA), Mason Graphite (LLG), BBX Capital (BBX), ArQule (ARQL), Infinera (INFN), Inovio Pharmaceuticals (INO), Selecta Biosciences (SELB), Fluent (FLNT) and Century Casinos (CNTY).

Who are BioNano Genomics' key executives?

BioNano Genomics' management team includes the folowing people:
  • Dr. Robert Erik Holmlin, Pres, CEO & Director (Age 51)
  • Mr. Michael J. Ward, Chief Financial Officer (Age 47)
  • Mr. Mark Borodkin, Chief Operating Officer (Age 45)
  • Mr. Warren Robinson, Chief Commercial Officer (Age 50)
  • Dr. Paul R. Selvin Ph.D., Scientific Advisor

When did BioNano Genomics IPO?

(BNGO) raised $16 million in an initial public offering on the week of August 20th 2018. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. Roth Capital Partners and Maxim Group served as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are BioNano Genomics' major shareholders?

BioNano Genomics' stock is owned by many different of institutional and retail investors. Top institutional investors include Monashee Investment Management LLC (2.45%), Worth Venture Partners LLC (0.80%) and Millennium Management LLC (0.48%). Company insiders that own BioNano Genomics stock include Christopher J Twomey, David L Barker, Domain Partners Viii, LP, Mark Borodkin and R Erik Holmlin. View Institutional Ownership Trends for BioNano Genomics.

Which major investors are buying BioNano Genomics stock?

BNGO stock was acquired by a variety of institutional investors in the last quarter, including Monashee Investment Management LLC, Worth Venture Partners LLC and Millennium Management LLC. Company insiders that have bought BioNano Genomics stock in the last two years include Christopher J Twomey, David L Barker, Domain Partners Viii, LP, Mark Borodkin and R Erik Holmlin. View Insider Buying and Selling for BioNano Genomics.

How do I buy shares of BioNano Genomics?

Shares of BNGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioNano Genomics' stock price today?

One share of BNGO stock can currently be purchased for approximately $4.74.

How big of a company is BioNano Genomics?

BioNano Genomics has a market capitalization of $47.87 million and generates $12 million in revenue each year. The company earns $-18,500,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis.

What is BioNano Genomics' official website?

The official website for BioNano Genomics is

How can I contact BioNano Genomics?

BioNano Genomics' mailing address is 9640 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121. The company can be reached via phone at 858-888-7600 or via email at [email protected]

MarketBeat Community Rating for BioNano Genomics (NASDAQ BNGO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  102
MarketBeat's community ratings are surveys of what our community members think about BioNano Genomics and other stocks. Vote "Outperform" if you believe BNGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BNGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel